ACOG Drops 'Lowest Dose, Shortest Time' Rule in First Menopause Overhaul Since 2014

The American College of Obstetricians and Gynecologists on Oct. 15 published what it called its most comprehensive menopause guidance to date, replacing a 2014 document that had left many clinicians and patients uncertain about when to start hormone therapy, how long to stay on it, and what to do when hormones weren't an option.

The new guideline, Clinical Practice Guideline No. 13, covers vasomotor symptoms (hot flashes and night sweats), sleep disturbance, and mood changes, and it contains 17 evidence-based recommendations, according to a statement reviewed by Healio. The document was published in Obstetrics & Gynecology.

The headline shift for patients is the retirement of the old "lowest dose for the shortest time" instruction. <cite index="22-15,22-16">That 2014 directive urged the lowest effective dose for the shortest possible time; the new guideline drops that blanket rule.</cite> <cite index="22-17">Instead, decisions about when and how to stop should be individualized and revisited regularly, and some women may reasonably continue past 60.</cite>

For patients without contraindications, the guidance is now unambiguous. <cite index="24-1">ACOG strongly recommends systemic menopausal hormone therapy, with estrogen and a progestogen in women with a uterus, or estrogen alone if endometrial protection isn't needed, for managing vasomotor symptoms and related sleep disturbance.</cite> Timing still matters, though. <cite index="23-5">For patients who choose hormone therapy, ACOG recommends initiating treatment before age 60 or within 10 years of the start of spontaneous menopause.</cite>

The scope of the update goes beyond hormones. <cite index="21-6">The new recommendations are the most comprehensive guidance on the management of menopause published by ACOG to date, covering treatment options for vasomotor symptoms in addition to sleep and mood changes,</cite> areas that prior guidance addressed only in passing.

For patients who can't or won't take hormones, the guideline formally adds two drug classes to the recommendation list. <cite index="20-12">Fezolinetant and elinzanetant, both neurokinin receptor antagonists, join recommended nonhormonal treatments, with distinct liver-monitoring requirements.</cite> <cite index="23-9">The guidance also discusses SSRIs and SNRIs for patients experiencing vasomotor symptoms, depression, or both.</cite>

One clarification matters clinically: the guideline draws a hard line between menopausal symptoms and clinical depression. <cite index="24-3,24-4">Current evidence is insufficient to recommend for or against hormone therapy for menopausal depression symptoms, and perimenopausal or postmenopausal women for whom depression is the predominant symptom, or who meet criteria for major depressive disorder, should be treated according to depression management guidelines.</cite> In plain terms, hormone therapy is not a substitute for depression care.

The guidance is also skeptical of the supplement aisle. <cite index="20-6">ACOG does not recommend phytoestrogens, herbal supplements, or other dietary supplements because evidence of efficacy and safety remains insufficient.</cite> Mind-body approaches fared better: <cite index="20-9">ACOG conditionally supports cognitive behavioral therapy for vasomotor, sleep, and mood symptoms, and mindfulness or exercise for sleep and mood.</cite>

The update arrives at a moment when patients are asking about menopause treatment in far larger numbers than they were a decade ago, driven partly by broader public conversation and partly by a generation of women who came of age after the Women's Health Initiative scared many clinicians off hormone therapy entirely. The WHI findings, published in 2002, were later reinterpreted as largely applicable to older postmenopausal women, not to women in early menopause, but the chilling effect on prescribing persisted for years.

<cite index="21-8">The updated guidance includes more information on timing the initiation of hormone therapy to maximize its benefits while minimizing overall risks to patients,</cite> which is the practical gap clinicians have been navigating without clear ACOG support. <cite index="21-9">ACOG recommends that initiating hormone therapy should be based on shared decision making, considering the patient's symptoms; benefits and risks based on age, medical history, and baseline risks of cardiovascular disease, breast cancer, and venous thromboembolism; and individualized treatment goals and priorities.</cite>

Shared decision making, in practice, requires time that many ob-gyn and primary care visits don't reliably provide. Whether the new guidance changes what happens in the exam room depends as much on reimbursement and scheduling as on the clinical evidence behind it.

Sources cited:
- ACOG News Release, Oct. 15, 2026 (https://www.acog.org/news/2026/10/acog-expands-recommendations-for-management-of-menopause-symptoms/)
- Healio Women's Health / OB-GYN, Oct. 15, 2026 (https://www.healio.com/news/womens-health-ob-gyn/20261015/acog-expands-guidance-on-treatment-for-menopause-symptoms)
- Epocrates Clinical Summary, Oct. 20, 2026 (https://www.epocrates.com/online/article/new-acog-guidance-expands-menopause-treatment-options)
- Paloma Health / Obstetrics & Gynecology guideline summary, Oct. 19, 2026 (https://www.palomahealth.com/learn/new-acog-menopause-guidelines-hormone-replacement-hrt)